Replimune (REPL) Capital Leases (2019 - 2026)
Replimune (REPL) posted Capital Leases of $21.9 million for Q1 2026, down 0.99% sequentially from $22.1 million in Q4 2025, and down 3.61% YoY from $22.7 million in Q1 2025.
Analysis
Replimune (REPL) Capital Leases (2019 - 2026) Analysis & Trends
Replimune has reported Capital Leases for 8 years, with the latest figure at $21.9 million in Q1 2026.
- Quarterly Capital Leases fell 3.61% year-over-year to $21.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.9 million (down 3.61% YoY) and the FY2026 annual result came in at $21.9 million, down 3.61% from the prior year.
- Capital Leases retreated to $21.9 million in Q1 2026 per REPL's latest filing, from $22.1 million in the prior quarter.
- Over five years, Capital Leases peaked at $24.4 million in Q1 2022 and troughed at $21.9 million in Q1 2026.
- A 5-year average of $23.3 million and a median of $23.4 million in 2024 frame the typical range for Capital Leases.
- The sharpest annual moves came in 2022 and 2026: Capital Leases fell 1.37% in 2022, then slipped 3.61% in 2026.
- Over 5 years, Capital Leases stood at $24.1 million in 2022, then dropped by 2.18% to $23.6 million in 2023, then fell by 2.75% to $22.9 million in 2024, then retreated by 3.42% to $22.1 million in 2025, then retreated by 0.99% to $21.9 million in 2026.
- According to Business Quant data, Capital Leases over the past three periods registered $21.9 million, $22.1 million, and $22.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Replimune | 1.45 Bn | 1.45 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.69 Mn |
| Mar 31, 2026 | 21.91 Mn |
| Dec 31, 2025 | 22.13 Mn |
| Sep 30, 2025 | 22.34 Mn |
| Jun 30, 2025 | 22.54 Mn |
| Mar 31, 2025 | 22.73 Mn |
| Dec 31, 2024 | 22.91 Mn |
| Sep 30, 2024 | 23.09 Mn |
| Jun 30, 2024 | 23.26 Mn |
| Mar 31, 2024 | 23.41 Mn |
| Dec 31, 2023 | 23.56 Mn |
| Sep 30, 2023 | 23.71 Mn |
| Jun 30, 2023 | 23.84 Mn |
| Mar 31, 2023 | 23.97 Mn |
| Dec 31, 2022 | 24.09 Mn |
| Sep 30, 2022 | 24.21 Mn |
| Jun 30, 2022 | 24.31 Mn |
| Mar 31, 2022 | 24.41 Mn |
| Dec 31, 2021 | 24.50 Mn |
| Sep 30, 2021 | 24.59 Mn |